$Rig's Platinum Penny Alerts

[stervc]

SOAN Liprostin™ 4x Faster than FDA Approved Cilostazol™

The SOAN (AngioSoma, Inc.) drug known as Liprostin™ works four times faster than an already FDA approved drug Cilostazol™ for treating intermittent claudication:

http://s642097301.onlinehome.us/liprostin
Data shows Liprostin™ is more than twice as effective as and four times faster than FDA approved drug Cilostazol™ for treating intermittent claudication.

To better understand the magnitude of this, the drug Cilostazol™ is part of the 29 Abbreviated New Drug Applications (ANDAs) that was acquired in Jan 2018 by CASI Pharmaceuticals Inc. which trades on the NASDAQ under the ticker of CASI at $6.52 per share and currently has $67.4 Million cash on hand:
http://www.casipharmaceuticals.com/

http://www.casipharmaceuticals.com/investor-relations/news/casi-pharmaceuticals-announces-second-quarter-and-first-half-2018

https://www.nasdaq.com/press-release/casi-pharmaceuticals-enters-strategic-partnering-and-contract-manufacturing-agreement-with-yiling-20180621-00230
Entecavir and cilostazol are part of the 29 abbreviated new drug applications (ANDAs) that CASI acquired from Sandoz in January 2018.

Potential $600,000,000 (six hundred million dollars) from Liprostin™ sales:

https://www.businesswire.com/news/home/20161005005425/en/AngioSoma-Announces-Liprostin%E2%84%A2-Focused-Joint-Venture
“If Liprostin™ treated ten percent (10%) of the 12 million untreated Peripheral Artery Disease patients in the U.S. as reported by The American Heart Association, this could produce a gross income of six hundred million dollars ($600 million) if we assumed the Company yields five hundred dollars ($500) per patient,” said Ms. Alexanderia K Blankenship, CEO & President of AngioSoma, Inc.

AngioSoma Inc. (SOAN) share structure details are below per OTC Markets:

https://www.otcmarkets.com/stock/SOAN/security
Authorized Shares (AS) = 480,000,000 Shares
Outstanding Shares (OS) = 63,003,596 Shares
Float = 12,488,734 Shares

This PR below strongly suggests two things for me regarding SOAN; either the company is going to get bought out or they are going to get FDA Approval with their drug called Liprostin™ of which I will reflect more about the drug following this PR below:

https://www.nasdaq.com/press-release/casi-pharmaceuticals-enters-strategic-partnering-and-contract-manufacturing-agreement-with-yiling-20180621-00230
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol

Agreement marks significant milestone for two of the 29 ANDAs acquired by CASI from Sandoz in January 2018

For inquiring minds, Sandoz is a wholly-owned subsidiary of Novartis which trades on the NYSE under the ticker of NVS at $81.00+ per share which generated $49.1 Billion in Net Sales, generated $7.7 Billion in Net Income, and has $10.4 Billion of Total Free Cash per their last Annual Report below:
https://www.sandoz.com/

https://www.novartis.com/

https://www.novartis.com/investors/novartis-annual-report/novartis-annual-report-2017

https://www.otcmarkets.com/stock/SOAN/security

http://angiosoma.info/

http://angiosoma.info/liprostin

As indicated above and underlined in green, SOAN is using a drug within its Liprostin™ drug that's in the queue for FDA Approval that is licensed by Pfizer that is already FDA Approved called Alprostadil which further leads me to think that FDA Approval for SOAN and its Liprostin™ is in the near future:

http://www.selleckchem.com/products/Alprostadil(Caverject).html


https://www.pfizermedicalinformation.com/en-us/patient/caverject-impulse-alprostadil


To further substantiate why I believe that either a buyout or an FDA Approval is in the near future for SOAN, take a look at their management team below and their credentials:

http://angiosoma.info/about/management-team-2
Alex K. Blankenship
Director, Chief Executive Officer & President


David P. Summers Ph.D.
Chairman Emeritus (a ceremonial position)




Scientific Advisory Board

http://angiosoma.info/about/scientific-advisory-board-2

v/r
Sterling